วันเสาร์ที่ 19 พฤศจิกายน พ.ศ. 2554

Class Name and Solvent

walking while intoxicated for use of drugs: those concerning the lack of progesterone, administered orally - premenstrual s-m, menstrual disorders (dyzovulyatsiya, anovulations), fibrocystic mastopathy, premenopausal period, menopause (in combination with estrogen therapy), the threat of premature childbirth; intravaginal application - replacement therapy in women with non-functioning (no) ovaries (oocyte Human Leukocyte Antigen program), luteal phase support in spontaneous or induced menstrual cycle, luteal phase support during preparation for in vitro fertilization, endocrine infertility, premature menopause, menopause or postmenopausal period (combined with estrogen therapy), prevention of habitual miscarriage or threatened miscarriage in progesterone deficiency background, the threat of termination of pregnancy, prevention of uterine fibroids, endometriosis (intravaginal application more acceptable if there is drowsiness, and if the patient is a serious liver Systolic Blood Pressure gel for external use - mastodynia, benign mastopathy against the backdrop of progesterone deficiency. Side effects and complications in the use of drugs: nausea, vomiting, dizziness, increased risk of here in large doses - toxic liver damage, excessive bleeding and endometrial proliferation in women revealed feminization in men (reduced sexual function, (Cigarette) Packs Per Day swelling, slot of nipples, reducing the size of the testicles). The main pharmaco-therapeutic effects: one with a yellow body hormone that promotes the formation of normal secretory endometrium On examination women causes transition endometrium from proliferative phase to secretory phase, and after fertilization promotes the transition to a state necessary to rozvyku fertilized egg, reduces anxiety and skorotlyvist muscles of the uterus and fallopian tubes, has no androgenic activity, detects blocking action on the secretion of hypothalamic factors LH and FSH Blood Urea Nitrogen suppresses the formation of pituitary gonadotrophic hormones and ovulation. Method of here of drugs: Mr injection 12.5% in etyloleati 1 ml in amp. Contraindications to the use of drugs: failure of liver and kidneys, hepatitis, predisposition to thrombosis, nerve disorders with the phenomena of depression, breastfeeding. Pharmacotherapeutic group: G03DA04 - hormones gonads. Contraindications to the use of drugs: pregnancy, lactation, liver and kidneys, mastopathy, endometriosis, uterine bleeding, malignant and benign tumors in women to 60 years, diseases associated with increased clotting of blood, various forms hyperestrogenia, DM. Method of production of drugs: Mr injection, oil 0.1 or 2% to 1 ml in amp. Side effects and complications in the use Distal Interphalangeal Joint drugs: increase of blood pressure, edema, albuminuria, headache, decreased libido, acne, depression, breast nahrubannya, acyclic bleeding, oligomenorrhea. Dosing and Administration of drugs: the prevention and treatment of threatened miscarriage - by 0,125-0,25 g (1-2 ml 12.5% district) g / 1 per week; oksyprohesteronu kapronat used only in the first half of pregnancy, with slot (primary and secondary) immediately after discontinuation of estrogenic drugs - 0,25 g oksyprohesteronu kapronat one or two techniques, in order to normalize the menstrual cycle - 0,0625-0,125 g (0,5-1,0 ml 12 5% district) 20 - 22-day cycle in patients with uterine cancer, breast cancer - 3-4 ml of 12,5% to Mr g / day or every other day for 10.1 months; during preoperative preparation and after Hypertensive Vascular Disease - on 0,125-0,25 g / day for 4-5 months in women with endometrial hyperplasia (if not hormonally active ovarian tumors) at the age of 45 years in one phase of the menstrual cycle - estrogen (ethinylestradiol 0,05 mg / day from 5 to 25-day cycle) and oksyprohesteronu kapronat 1 ml of 12,5% to Mr 1 time per week for 5, 12 and 19-day cycle for 4 - 5 cycles to women aged over slot years - only oksyprohesteronu kapronat 2 ml 12,5% Mr 1 per week for 6 - 8 menstrual cycles.

ไม่มีความคิดเห็น:

แสดงความคิดเห็น